CONCEPTO NIPT

Concepto NIPT is a safe and non-Invasive screening test that uses cell free DNA (cf DNA) found in maternal blood to detect chromosomal anomalies accurately, starting from WEEK 10 of pregnancy

Safe and simple, single blood draw.

Optional gender detection.

Sex chromosome aneuploidies

Concepto NIPT Standard

Trisomy 21, 18 and 13.

Concepto NIPT Advance

Trisomy 21, 18 and 13,
Sex chromosome aneuploidies.

POWERED BY illumina

Ilumina® and the Powered by Illumina™ logo are trademarks of Illumina, Inc. in the U.S. and other countries.

What is Trisomy?

Normally, all cells in the human body have 46 chromosomes, made up of 23 pairs of chromosomes. These 23 pairs of chromosomes contain all of the DNA to determine the health of the baby. Certain genetic anomalies can occur when a baby develops three copies of a particular chromosome instead of two. The risk of having a chromosomal condition increases as the mother gets older.

Why should I take the test?

NIPT detects the possible anomalies at a very early stage, i.e., Week 10, with a high degree of accuracy and low false-positive rate.

How does the test work?

It involves a simple blood draw from the arm of the pregnant woman. The blood sample contains maternal and fetal DNA. Non-Invasive Pre-Natal tests can help identify if your baby is likely to have a chromosomal condition.

How accurate is it?

Concepto NIPT has >99% detection rate for aneuploidies.



Down Syndrome (Trisomy 21)
Edward Syndrome (Trisomy 18)
Patau Syndrome (Trisomy 13)

NIPT offering objectives

- Reduce exposure of fetus to risk
- Reduce false positives
- Easily offered to all pregnant women
- Enable a high detection rate
- Endorsed by society guidelines

Key Features

- Low contamination risk
- Fast
- Simple
- Non-invasive
- Accurate
- Affordable

NIPT Technology Highlights

Illumina's VeriSeq NIPT Solution v2 approach allows samples with low fetal fraction to be reported as strict FF cut-off may exclude patients with a high risk of aneuploidy from getting a result.

VeriSeq NIPT Solution v2 uses a dynamic threshold, which reduces NIPT failure rate to only 1.2% while ensuring accurate calls.

The VeriSeq NIPT Solution v2 dynamic threshold testing metric is known as iFACT and enables calls at low FFs by considering FF in combination with sequencing coverage.

From sample preparation to analysis, all it takes to deliver results is upto 5 working days thus, delivering large volumes of data in a short amount of time.

Latest whole genome sequencing technology provides a high-resolution, base-by-base view of the genome, captures both large and small variants that might be missed with targeted approaches.

The Science Behind NIPT





Sample collection | Sequencing | Analysis and Reporting

Is it safe for mother and child?

It involves a simple and safe blood draw from the arm of the expectant mother. Being non-invasive, it is completely safe for mother and baby.

How to take this test?

Fill in the details, book the appointment and visit the location for sample collection.

What are sex chromosome aneuploidies?

Sex chromosome anomalies (SCA) occur when there is a missing, extra or partial/incomplete sex chromosome (X or Y).

The Concepto-NIPT looks for SCAs such as:

X(O) - Turners Syndrome A condition affecting females, due to partially or completely missing sex chromosome. Most of them can lead a normal life with regular medical care.

XXY - Klinefelter's syndrome is an aneuploid genetic condition where a male has an additional copy of the X chromosome. The primary features are infertility and small, poorly functioning testicles.

XYY- Jacob's syndrome is a genetic condition having an extra copy of the Y chromosome in each of a male's cells, the chromosomal change sometimes causes no unusual physical features.

XXX- Triple X syndrome A genetic disorder characterized by the presence of an additional X chromosome in female children. They are often taller than average girls.

About Concepto

Concepto is an award-winning, majority-employee owned, trusted, and diverse British healthcare company with a decade of experience in serving the preventative healthcare needs of customers across Diagnostics, Genomics, Wellness, and Nutrition.

Concepto provides reliable and affordable care for hundreds of thousands of customers at its CQC-regulated clinics and UKAS-accredited state-of-the-art lab. Concepto is one of the very few global partners of Illumina Inc.

Awards & Accreditations

Chamber of Conscience
A Network of Goodwill

SME
HERTFORDSHIRE
Business Awards
2022
GOLD WINNER

Care Quality Commission

UKAS
MEDICAL
22226
Accredited to
ISO 15189:2012

UK Health Security Agency

INVESTORS IN PEOPLE

Trustpilot
TrustScore 4.7 | 17,373 reviews

Why Illumina?

Founded in
1998

Cumulative sequencing installed base
>20,000

Countries served
>140

About Illumina

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California, and it serves more than 140 countries. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.

Regonitions

POWERED BY illumina

Ilumina® and the Powered by Illumina™ logo are trademarks of Illumina, Inc. in the U.S. and other countries.